Titlebook: Cardiac Arrhythmias: New Therapeutic Drugs and Devices; Proceedings of the S Joel Morganroth,E. Neil Moore Conference proceedings 1985 Mart

machination

collagenase

Status of Class III Antiarrhythmic Drugs: Amiodarone, Bretylium and Sotalols unrelated to cardiac arrhythmias. Therefore, it is important to remember that their development was not guided by the intention to develop an ideal antiarrhythmic agent. As Dr. Vaughan Williams has said :

藕床生厭倦

Sudden Death as an End-Point for the Clinical Evaluation of Antiarrhythmic Drugs a subsequent reduction in the risk of dysrhythmic deaths. Thus, it is appropriate to consider whether sudden death can be adequately identified as a dysrhythmic event so that it can be used as an end-point for a clinical trial evaluating antiarrhthymic agents.

急急忙忙

古董

Ptosis

Procainamide, Quinidine, Disopyramide, Cibenzoline, Pirmenol — Efficacy in the Treatment of Ventricutoriness, depressing membrane excitability, membrane responsiveness, and automaticity in normal Purkinje fibers.. The current status of cibenzoline and pirmenol, two investigational agents for the treatment of ventricular rhythm disturbances, are also reviewed. Both these drugs share many electrophysiologic properties with the Type IA drugs.

VALID

Holter/Exercise and Electrophysiologic Methods for Evaluating Drug Therapy for Malignant Ventricularluding runs of unsustained VT. When antiarrhythmic drug treatment is stopped, electrophysiologic studies are capable of inducing sustained VT or VF in about 80% of those who present with recurrent sustained VT as the clinical arrhythmia and in about 70% of those who had a cardiac arrest and were found in VF (1–4).

新娘

https://doi.org/10.1007/978-0-8176-8265-1 a subsequent reduction in the risk of dysrhythmic deaths. Thus, it is appropriate to consider whether sudden death can be adequately identified as a dysrhythmic event so that it can be used as an end-point for a clinical trial evaluating antiarrhthymic agents.

interrupt

逗留

Initial Evaluation of New Antiarrhythmic Agents in Man: Normal Volunteers or Patients? of new chemical entities has evolved which attempts to maximize safety and protect the patient/volunteer. Under the usual scheme of things, following extensive toxicological evaluation in animals, a candidate drug is administered to apparently healthy human subjects, most often young adult males, i